Thomas G. Martin, MD

Articles by Thomas G. Martin, MD

Thomas Martin, MD, on Exciting Cell Therapy Options in Multiple Myeloma

June 23rd 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed cilta-cel and upcoming cell therapies.

Improving Access to CAR T-Cell Therapies: Thomas G. Martin, MD

ByThomas G. Martin, MD

March 12th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed potential effects of cilta-cel's approval.

Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD

ByThomas G. Martin, MD

February 16th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.

Cilta-Cel in the Multiple Myeloma Treatment Landscape: Thomas G. Martin, MD

ByThomas G. Martin, MD

January 27th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.

Cilta-Cel's Efficacy in Heavily Pretreated Patients With Multiple Myeloma: Thomas G. Martin, MD

ByThomas G. Martin, MD

January 19th 2022

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from the CARTITUDE-1 study presented at ASH 2021.

Utility of CAR T-Cell Therapy in Relapsed Multiple Myeloma: Thomas G. Martin, MD

ByThomas G. Martin, MD

November 27th 2021

The co-leader of Cancer Immunology & Immunotherapy Program, UCSF Helen Diller Family Comprehensive Cancer Center discussed he utility of CAR T-cell therapy in late relapsed multiple myeloma.